As cis P-tau is an early driver and biomarker for incipient and preclinical AD, stroke/VaD, TBI/CTE and cis P-tau mAb is in clinical trials, our results not only discover an early disease driver, but also offer an early biomarker and effective antibody therapy for PE. The gene discussed is MAPT; the disease is Alzheimer disease.